How familial cancer genes and environmentally induced oncogenes have changed the endocrine landscape

Modern Pathology

Volumn 14, Issue 3, 2001, Pages 246-253

  Asa, S L ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Medullary carcinoma; Papillary thyroid carcinoma; Ret proto oncogene; Ret rearrangements; Thyroid

Indexed keywords

CANCER SCREENING; CANCER SUSCEPTIBILITY; GENE REARRANGEMENT; GENETIC RISK; GENETIC SCREENING; HISTOPATHOLOGY; HUMAN; ONCOGENE RET; PRIORITY JOURNAL; REVIEW; RISK MANAGEMENT; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY;

ADENOCARCINOMA; CARCINOMA, MEDULLARY; CARCINOMA, PAPILLARY; DROSOPHILA PROTEINS; GENE REARRANGEMENT; GENETIC SCREENING; HUMANS; HYPERPLASIA; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR PROTEIN-TYROSINE KINASES; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0035087297     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3880293     Document Type: Review

References (89)

1. C-cell hyperplasia preceding medullary thyroid carcinoma
2. The pathobiology of the human calcitonin (C)-cell: A review
3. Reevaluation of histologic criteria for C-cell hyperplasia in MEN 2A using genetic recombinant markers
4. C-cell hyperplasia in thyroid tissue adjacent to follicular cell tumors
5. Symptomatic C-cell hyperplasia associated with chronic lymphocytic thyroiditis
6. C-cell hyperplasia accompanying thyroid diseases other than medullary carcinoma: An immunocytochemical study by means of antibodies to calcitonin and somatostatin
7. C-cell hyperplasia of the thyroid in a patient with goitrous hypothyroidism and Hashimoto's thyroiditis
8. Assignment of multiple endocrine neoplasia type 2A to chromosome 10 by linkage
9. Mapping, the inherited defects associated with multiple endocrine neoplasia type 2A, multiple endocrine neoplasia type 2B, and familial medullary thyroid carcinoma to chromosome 10 by linkage analysis
10. The mutation for medullary thyroid carcinoma with parathyroid tumors (mTC with PTs) is closely linked to the centromeric region of chromosome 10
11. Low incidence of loss of chromosome 10 in sporadic and hereditary human medullary thyroid carcinoma
12. Activation of a novel human transforming gene, ret, by DNA rearrangement
13. cDNA cloning of mouse ret proto-oncogene and its sequence similarity to the cadherin superfamily
14. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
15. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma
16. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours
17. Single missense mutation in the tyrosine kinase catalytic domain of the RET proto-oncogene is associated with multiple endocrine neoplasia type 2B
18. Expression of the ret proto-oncogene product in human normal and neoplastic tissues of neural crest origin
19. The ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas
20. Expression of the c-ret proto-oncogene during mouse embryogenesis
21. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor RET
22. Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease
23. Mutations of the RET proto-oncogene in Hirschsprung's disease
24. Functional receptor for GDNF encoded by the c-ret proto-oncogene
25. GDNF signalling through the RET receptor tyrosine kinase
26. GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-α, a novel receptor for GDNF
27. Characterization of a multicomponent receptor for GDNF
28. Glial cell line-derived neurotrophic factor-dependent RET activation can be mediated by two different cell-surface accessory proteins
29. Development of medullary thyroid carcinoma in transgenic mice expressing the RET proto-oncogene altered by a multiple endocrine neoplasia type 2A mutation
30. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B
31. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC
32. The ret proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease
33. MEN2b-transgenic mice
34. The multiple endocrine neoplasia type 2B point mutation switches the specifidity of the RET tyrosine kinase towards, cellular substrates that are susceptible to inerract wth Crk and Nck
35. Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma
36. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A
37. A rapid screening method for the detection of mutations in the RET proto-oncogene in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma families
38. Identification of multiple endocrine neoplasia, type 2 gene carriers using linkage analysis and analysis of the ret proto-oncogene
39. Frequent RET proto-oncogene mutations in multiple endocrine neoplasia type 2A
40. A rapid screening method for the detection of mutations in the RET proto-oncogene in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma families
41. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A
42. The ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas
43. Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas
44. A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases
45. Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype
46. Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC
47. Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory R1α of cyclic AMP-dependent protein kinase A
48. Molecular characterization of RET/PTC3; a novel rearranged version of the RET proto-oncogene in a human thyroid papillary carcinoma
49. A t(10;17) translocation creates the RET/PTC2 chimeric transforming sequence in papillary thyroid carcinoma
50. Molecular and biochemical analysis of RET/PTC4, a novel oncogenic rearrangement between RET and ELE1 genes, in a post-Cherynobyl papillary thyroid cancer
51. High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident
52. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinoma in children
53. A new form of RET rearrangement in thyroid carcinomas of children after the Chernobyl reactor acident
54. Detection of a novel type of RET rearrangement (PTC5) in thyroid carcinomas after Chernobyl and analysis of the involved RET-fused gene RFG5
55. Chromosomal breakpoint positions suggest a direct role for radiation in inducing illegitimate recombination between the ELE1 and RET genes in radiation-induced thyroid carcinomas
56. RET activation in adult and childhood papillary thyroid carcinoma using a reverse transcriptase-polymerase chain reaction approach on archival-nested material
57. Detection of the PTC/retTPC oncogene in human thyroid cancers
58. ret/PTC-1,-2 and -3 oncogene rearrangements in human thyroid carcinomas: Implications for metastatic potential?
59. ret/Ptc-1, -2, and -3 oncogene rearrangements in human thyroid carcinomas: Implications for metastatic potential?
60. Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas
61. Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice
62. The RET/PTC3 oncogene: Metastatic solid-type papillary carcinomas in murine thyroids
63. Detection of phosphorylated ret/TPC oncogene product in cytoplasm
64. Leucine zipper-mediated dimerization is essential for the PTC1 oncogenic activity
65. Expression of the RET/PTC1 oncogene impairs the activity of TTF-1 and Pax-8 transcription factors
66. Papillary thyroid carcinoma oncogene (RET/PTC) alters the nuclear envelope and chromatin structure
67. Mitogenic signaling by Ret/ptc2 requires association with enigma via a LIM domain
68. RET/PTC oncogene activation is an early event in thyroid carcinogenesis
69. Distinct multiple ret/PTC gene rearrangements in multifocal papillary thyroid neoplasia
70. High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: A strong correlation between RET/PTC3 and the solid-follicular variant
71. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children
72. Sporadic ret-rearranged papillary carcinoma of thyroid: A subset of slow growing, less aggressive thyroid neoplasms?
73. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes
74. Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto's thyroiditis
75. Occult micropapillary carcinoma associated with benign follicular thyroid disease and unrelated thyroid neoplasms
76. Tumors of the thyroid gland
77. The WHO histological classification of thyroid tumors: A commentary on the second edition
78. Hürthle cell lesions of the thyroid gland
79. Hürthle cell (oxyphilic) papillary thyroid carcinoma: A variant with more aggressive biologic behavior
80. Papillary carcinoma of the thyroid, oxyphil cell type, "clear cell" variant. A light and electron microscopic study
81. Oxyphilic (Askenasy/Hürthle cell) tumors of the thyroid. Microscopic features predict biologic behavior
82. Hürthle cell variant of papillary carcinoma of the thyroid gland
83. Papillary Hürthle cell carcinoma with lymphocytic stroma. "Warthin-like tumor" of the thyroid
84. Oxyphilic papillary thyroid carcinoma
85. Molecular basis of Hurthle cell papillary thyroid carcinoma
86. RET/PTC activation in hyalinizing trabecular tumors of the thyroid
87. Hyalinizing trabecular tumor of the thyroid: A variant of papillary carcinoma proved by molecular genetics
88. Molecular genetic analysis refines the fine needle aspiration diagnosis of thyroid cancer